title: Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review.
abstract: Vascular calcification (VC) is highly prevalent in patients with chronic kidney disease (CKD) and is strongly associated with cardiovascular mortality and morbidity. Accumulating evidence over the past decade has challenged the hypothesis of close interaction between bone and VC what raises the possibility of a common underlying pathophysiological mechanism. Lately, bone regulatory proteins such as: osteoprotegerin (OPG) and Receptor Activator for Nuclear Factor κB Ligand (RANKL) has attracted attention of researchers as a possible key mediators of bone-vascular calcification imbalance. The literature search was carried out using the MEDLINE/PubMed database and a combination of keywords and MeSH terms, and only papers published since January 2005 to July 2016 were selected. The search resulted in 562 potential articles. After selection according to the eligibility criteria, 107 studies fulfilled were included (102 full texts and 5 was case reports). OPG and RANKL plays essential role in the regulation of bone metabolism and may be regarded as a possible link between VC, bone and mineral metabolism in CKD patients. Further studies are required to determine the diagnostic significance of these proteins in evaluation of progression and severity of VC process in CKD patients. Finally, the efficacy and safety, especially in regard to VC, of anti-RANKL therapy in CKD patients requires well-designed prospective, randomized trials.
authors.affiliation: Department of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Beata
authors.initials: B
authors.lastname: Znorko
authors.affiliation: Department of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Oksztulska-Kolanek
authors.affiliation: Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Michałowska
authors.affiliation: Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Kamiński
authors.affiliation: Department of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland. Electronic address: krystynapawlak@poczta.onet.pl.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Pawlak
mesh_terms: D000818:Animals; D001847:Bone Diseases / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D053244:Osteoprotegerin / Q000378:metabolism*; D053245:RANK Ligand / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000378:metabolism / Q000473:pathology*; D014652:Vascular Diseases / Q000378:metabolism / Q000473:pathology*
chemical_list: D053244:Osteoprotegerin; D053245:RANK Ligand
keywords: Chronic kidney disease; Osteoprotegerin; RANKL; Vascular calcification